E2F signature is predictive for the pancreatic adenocarcinoma clinical outcome and sensitivity to E2F inhibitors, but not for the response to cytotoxic-based treatments

The main goal of this study was to find out strategies of clinical relevance to classify patients with a pancreatic ductal adenocarcinoma (PDAC) for individualized treatments. In the present study a set of 55 patient-derived xenografts (PDX) were obtained and their transcriptome were analyzed by usi...

Descripción completa

Detalles Bibliográficos
Autores principales: Lan, Wenjun, Bian, Benjamin, Xia, Yi, Dou, Samir, Gayet, Odile, Bigonnet, Martin, Santofimia-Castaño, Patricia, Cong, Mei, Peng, Ling, Dusetti, Nelson, Iovanna, Juan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5974374/
https://www.ncbi.nlm.nih.gov/pubmed/29844366
http://dx.doi.org/10.1038/s41598-018-26613-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5974374/
https://www.ncbi.nlm.nih.gov/pubmed/29844366
http://dx.doi.org/10.1038/s41598-018-26613-z

Ejemplares similares